BMY vs SMMT: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BMY and SMMT share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BMY and SMMT exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. It makes money primarily by selling patented branded drugs, with a portfolio that has historically leaned on blockbuster franchises such as the blood thinner Eliquis (co-marketed with Pfizer), the cancer immunotherapy Opdivo, and the multiple myeloma drug Revlimid. The company is navigating a major patent cliff as several legacy products lose exclusivity, and it is rebuilding growth through a newer portfolio that includes drugs like Reblozyl, Opdualag, Camzyos, Sotyktu, and the schizophrenia treatment Cobenfy (acquired through Karuna). Bristol Myers grows both organically through its research pipeline and through large acquisitions (Celgene, MyoKardia, Karuna, Mirati). It is headquartered in New York and operates worldwide.

Full BMY guide

Summit Therapeutics is a clinical-stage biopharmaceutical company focused almost entirely on ivonescimab, a first-in-class tetravalent bispecific antibody that targets both PD-1 and VEGF simultaneously. Summit in-licensed ivonescimab from China's Akeso in January 2023 and holds rights to develop and commercialize it across North America, South America, Europe, the Middle East, Africa, and Japan, while Akeso keeps China and certain other regions. The lead opportunity is non-small cell lung cancer (NSCLC), where Phase III data have shown ivonescimab extending progression-free survival versus Merck's Keytruda (pembrolizumab), plus additional programs in colorectal and other cancers. The company generates no meaningful product revenue yet and funds operations from its cash balance while running large global trials.

Full SMMT guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BMY drivers: New product portfolio ramp; Oncology and immunology depth.
• SMMT drivers: Ivonescimab FDA review and first approval; Head-to-head data versus Keytruda.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. For SMMT, summit is a pre-revenue, single-asset biotech, so its outcome depends overwhelmingly on ivonescimab; a failed trial, a negative or delayed FDA decision, or unexpected safety findings could sharply reduce the company's value.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BMY if you believe its drivers more; SMMT if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BMY and SMMT guides.

BMY. Bristol Myers tends to trade at a low forward earnings multiple relative to large-cap pharma peers, reflecting market skepticism about its ability to replace patent-cliff revenue. The high dividend yield and strong free cash flow are the bull-case anchors, while the depressed valuation reflects the bear case that legacy declines outrun newer products.

SMMT. As a clinical-stage biotech with no meaningful product sales, Summit cannot be valued on earnings or a P/E ratio; its roughly $12 billion market value (July 2026) reflects expectations for ivonescimab rather than current financials. Standard metrics like revenue and profit are near zero, so investors weigh trial data, the market size of NSCLC, and cash runway instead. Valuation is therefore speculative and can move dramatically on a single readout or regulatory event.

Headline figures (approximate, early 2026): BMY shows revenue (ttm) ~$48 billion, operating margin ~20% (varies with acquisition charges), net income (ttm) volatile, pressured by large acquisition write-offs, dividend yield ~4-5%; SMMT shows product revenue (ttm) ~$0 (pre-commercial), cash & short-term investments (q1 2026) ~$598.7 million, quarterly operating cash burn (q1 2026) ~$122.3 million, market cap ~$12 billion.

BMY and SMMT are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BMY and SMMT exposure against your real portfolio. It is not an investment adviser.